دورية أكاديمية
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort
| العنوان: | Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort |
|---|---|
| المؤلفون: | Teira, Ramon, Diaz-Cuervo, Helena, Aragão, F, Castaño, Manuel, Romero, Alberto, Roca, Bernardino, Deig, Elisabeth, Curran Fàbregas, Adria |
| المساهمون: | Teira R Service of Internal Medicine, Hospital de Sierrallana, Torrelavega, Spain. Diaz-Cuervo H Gilead Sciences, MAOR, London, UK. Aragão F Maple Health Group, New York City, NY, USA. NOVA National School of Public Health, Public Health Research Centre, Unversidade NOVA de Lisboa, Lisboa, Portugal. Castaño M Hospital Regional Universitario de Málaga, Málaga, Spain. Romero A Hospital Universitario de Puerto Real, Puerto Real, Spain. Roca B Hospital General de Castellón, Castellón, Spain. Deig E Hospital General de Granollers, Granollers, Spain. Currán A Vall d’Hebron Hospital Universitari, Barcelona, Spain, Hospital General de Granollers |
| المصدر: | Scientia |
| بيانات النشر: | Springer |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | VIH (Virus) - Tractament, Medicaments - Efectes fisiològics, Medicaments - Eficàcia, DISEASES::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia |
| الوصف: | HIV; Triple therapy; Two-drug combinations ; VIH; Triple teràpia; Combinacions de dos fàrmacs ; VIH; Terapia triple; Combinaciones de dos medicamentos ; Introduction: Standard therapy for HIV treatment has consisted of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug regimens (2DR) has been considered for selected patients in part to avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-world outcomes of integrase inhibitor (INSTI)-based three-drug regimens (3DR) versus 2DR of dolutegravir (DTG) + rilpivirine (RPV) or DTG + lamivudine (3TC). Methods: All patients in the Spanish VACH cohort switching to INSTI-based 3DR or a 2DR consisting of DTG + RPV or DTG + 3TC between May 2, 2016 and May 15, 2019 were included. Kaplan-Meier curves and Cox proportional hazard models were used to assess time to/risk of discontinuation due to treatment failure (TF) (defined as virologic failure [VF], immunologic failure, or disease progression) and adverse events (AEs). Three secondary analyses were performed: (1) in restricting the analysis to patients who were virologically suppressed (HIV RNA < 50 copies/mL) at switch; (2) matched analysis (2:1, matched by age, sex, number of previous VFs, and line of regimen), and (3) using VF as the primary endpoint in all patients. Results: Overall, 5047 3DR and 617 2DR patients were analyzed. Baseline characteristics differed between groups; 2DR patients were older, more treatment experienced, and more likely to be virologically suppressed at switch. Time to discontinuation due to TF was significantly shorter for 2DR (P = 0.002). The hazard ratio (HR) for discontinuation due to TF on 2DR vs 3DR was 2.33 (P = 0.003). No difference was observed for time to discontinuation (P = 0.908) or risk of discontinuation due to AEs (HR = 0.80; P = 0.488). Results were qualitatively similar in virologically suppressed patients, matched analysis, and for VF. Conclusion: In the real world, the risks of ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 35399147 |
| العلاقة: | Infectious Diseases and Therapy;11; https://doi.org/10.1007/s40121-022-00630-yTest; Teira R, Diaz-Cuervo H, Aragão F, Castaño M, Romero A, Roca B, et al. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort. Infect Dis Ther. 2022 Apr 11;11:1177-92.; https://hdl.handle.net/11351/7940Test |
| DOI: | 10.1007/s40121-022-00630-y |
| الإتاحة: | https://doi.org/10.1007/s40121-022-00630-yTest https://hdl.handle.net/11351/7940Test |
| حقوق: | Attribution-NonCommercial-ShareAlike 4.0 International ; http://creativecommons.org/licenses/by-nc-sa/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.99667D5E |
| قاعدة البيانات: | BASE |
| تدمد: | 35399147 |
|---|---|
| DOI: | 10.1007/s40121-022-00630-y |